A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 462-471

  Chowdhury, Aparajita ^a   Chowdhury, Sanjib ^a   Tsai, Ming Ying ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

A; Aurora; MK 8745; Non Hodgkin lymphoma; TPX2

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA A KINASE; BIOLOGICAL MARKER; CASPASE 3; CASPASE 7; MK 8745; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TARGETING PROTEIN FOR XENOPUS KINASE LIKE PROTEIN 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; DNA FRAGMENTATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TETRAPLOIDY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LYMPHOMA, NON-HODGKIN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIAZOLES; TRANSCRIPTION FACTORS; XENOPUS LAEVIS; XENOPUS PROTEINS;

EID: 84857519589     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.619018     Document Type: Article

References (44)

1. V ader G, Lens SM. Th e Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72.
2. C armena M, Earnshaw WC. Th e cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-854. (Pubitemid 37411723)
3. L iu Q, Kaneko S, Yang L.et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004;279:52175-52182. (Pubitemid 39656591)
4. O uchi M, Fujiuchi N, Sasai K.et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004;279:19643-19648. (Pubitemid 38623401)
5. Yang H, Ou CC, Feldman RI.et al. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004;64:463-467. (Pubitemid 38120883)
6. U lisse S, Baldini E, Toller M.et al. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer 2007;14: 827-837. (Pubitemid 350074070)
7. Briassouli P, Chan F, Savage K.et al. Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 2007;67:1689-1695. (Pubitemid 46383395)
8. Bayliss R, Sardon T, Vernos I.et al. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003;12:851-862. (Pubitemid 37352779)
9. Kufer TA, Sillje HH, Korner R.et al. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002;158:617-623. (Pubitemid 34920101)
10. W ittmann T, Wilm M, Karsenti E.et al. TPX2, a novel xenopus MAP involved in spindle pole organization. J Cell Biol 2000;149:1405-1418. (Pubitemid 30437615)
11. H irota T, Kunitoku N, Sasayama T.et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-598. (Pubitemid 37159255)
12. P ugacheva EN, Jablonski SA, Hartman TR.et al. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007;129:1351-1363. (Pubitemid 46962087)
13. M olli PR, Li DQ, Bagheri-Yarmand R.et al. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol 2010;190:101-114.
14. Dar AA, Goff LW, Majid S.et al. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Th er 2010;9:268-278.
15. N icolaides C, Dimou S, Pavlidisa N. Prognostic factors in aggressive non-Hodgkins Lymphomas. Oncologist 1998;3:189-197. (Pubitemid 28307450)
16. Gautschi O, Mack PC, Davies AM.et al. Aurora kinase inhibitors: A new class of targeted drugs in cancer. Clin Lung Cancer 2006;8:93-98. (Pubitemid 44596750)
17. Hata T, Furukawa T, Sunamura M.et al. RNA interference targeting Aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65:2899-2905. (Pubitemid 40490094)
18. K een N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-936. (Pubitemid 39626216)
19. Yakushijin Y, Hamada M, Yasukawa M. Th e expression of the Aurora-A gene and its signifi cance with tumorgenesis in non-Hodgkins lymphoma. Leuk Lymphoma 2004;45:1741-1746. (Pubitemid 38997139)
20. Cheung CH, Coumar MS, Hsieh HP.et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18: 379-398.
21. T sai MY, Wiese C, Cao K.et al. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat Cell Biol 2003;5:242-248. (Pubitemid 36322252)
22. Telford WG, King LE, Fraker PJ. Evaluation of glucocorticoidinduced DNA fragmentation in mouse thymocytes by fl ow cytometry. Cell Prolif 1991;24:447-459.
23. Iqbal J, Weisenburger DD, Chowdhury A.et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011;25:1377.
24. S himomura T, Hasako S, Nakatsuru Y.et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Th er 2010;9:157-166
25. Aurora B kinase activity in human cells. Cell Cycle 2007;6:2846-2854.
26. C arpinelli P, Ceruti R, Giorgini ML.et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profi le relevant to cancer. Mol Cancer Th er 2007;6:3158-3168.
27. G uo J, Anderson MG, Tapang P.et al. Identifi cation of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 2009;9:90-102.
28. L in ZZ, Hsu HC, Hsu CH.et al. Th e Aurora kinase inhibitor VE-465 has anticancer eff ects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009;50:518-527.
29. H irota T, Lipp JJ, Toh BH.et al. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 2005;438:1176-1180. (Pubitemid 41831689)
30. B ortner CD, Oldenburg NB, Cidlowski JA. Th e role of DNA fragmentation in apoptosis. Trends Cell Biol 1995;5:21-26.
31. S cott FL, Denault JB, Riedl SJ.et al. XIAP inhibits caspase-3 and -7 using two binding sites: Evolutionarily conserved mechanism of IAPs. EMBO J 2005;24:645-655. (Pubitemid 40343265)
32. M ao JH, Wu D, Perez-Losada J.et al. Crosstalk between Aurora-A and p53: Frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007;11:161-173. (Pubitemid 46209850)
33. H ill R, Bodzak E, Blough MD.et al. p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle 2008;7:2535-2543.
34. G illis LD, Leidal AM, Hill R.et al. p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle 2009;8: 253-256.
35. , Belkhiri A, Ecsedy J.et al. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-defi cient cancer cells. Cancer Res. 2008;68:8998-9004.
36. Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007;26: 301-310. (Pubitemid 46617338)
37. Andersen JL, Johnson CE, Freel CD.et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J 2009;28:3216-3227.
38. Qin L, Tong T, Song Y.et al. Aurora-A interacts with cyclin B1 and enhances its stability. Cancer Lett 2009;275:77-85.
39. Sardon T, Peset I, Petrova B.et al. Dissecting the role of Aurora A during spindle assembly. EMBO J 2008;27:2567-2579.
40. Kinoshita K, Noetzel TL, Pelletier L.et al. Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol 2005;170:1047-1055. (Pubitemid 41362637)
41. Kim M, Gans JD, Nogueira C.et al. Comparative oncogenomics identifi es NEDD9 as a melanoma metastasis gene. Cell 2006;125: 1269-1281. (Pubitemid 43949521)
42. O ' N eill GM, Seo S, Serebriiskii IG.et al. A new central scaff old for metastasis: Parsing HEF1/Cas-L/NEDD9. Cancer Res. 2007;67: 8975-8979. (Pubitemid 47535876)
43. O zlu N, Srayko M, Kinoshita K.et al. An essential function of the C. elegans ortholog of TPX2 is to localize activated aurora A kinase to mitotic spindles. Dev Cell 2005;9:237-248. (Pubitemid 41051742)
44. A nderson K, Yang J, Koretke K.et al. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 2007;46: 10287-10295. (Pubitemid 350067622)